


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+0.99%
+2.09%
+1.29%
+16.61%
REGN
Regeneron Pharma
$796.55
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market

Trading below its fair value
Risk Analysis

Investors losing their confidence
REGN Price Performance
$741.29 (+7.45%)
$576.42 (+38.19%)
$571.78 (+39.31%)
$686.33 (+16.06%)
REGN has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

REGN overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors losing their confidence
Future
Future

Earnings are forecast to grow

Outperform the market

Trading below its fair value
![]()
REGN Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
REGN Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
SNY
49.03
+1.87%
NVS
141.54
+0.06%
TEVA
32.01
-1.54%
MRK
110.53
-0.41%
OPK
1.37
-0.36%
What is REGN current stock price?
What are REGN stock strengths?
What is REGN Risk Level?
What is REGN market cap and volume?
What is REGN current Stock IQ?
Should I buy REGN stock right now?
Is REGN a Strong Buy right now?
What does a 'Strong Buy' rating mean for REGN?
What does a 'Strong Sell' rating mean for REGN?
What factors influence REGN's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+0.99%
+2.09%
+1.29%
+16.61%
REGN
Regeneron Pharma
Current Price
$796.55
REGN Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market

Trading below its fair value
Risk Analysis

Investors losing their confidence
Linked to REGN
SNY
49.03
+1.87%
NVS
141.54
+0.06%
TEVA
32.01
-1.54%
MRK
110.53
-0.41%
OPK
1.37
-0.36%

REGN Price Performance
$741.29 (+7.45%)
$576.42 (+38.19%)
$571.78 (+39.31%)
$686.33 (+16.06%)
REGN Analysts Opinion
REGN Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors losing their confidence
Future
Future

Earnings are forecast to grow

Outperform the market

Trading below its fair value
![]()
REGN Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
REGN Street Sentiment is extremely bullish and have positive views on the near-term outlook
REGN has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
REGN Latest Analysis
Regeneron (REGN) Upgraded to Strong Buy: What Does It Mean for the Stock?. Regeneron (REGN) might move higher on growing optimism about its earnings prospects which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Fri Jan 9, 2026
Looking At Regeneron Pharmaceuticalss Recent Unusual Options Activity. Investors with a lot of money to spend have taken a bearish stance on ).And retail traders should know.We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals we don'.t know. But when something this big happens with REGN it often means somebody knows something is about to happen.Today Benzinga'.s
Thu Jan 8, 2026
REGN Crosses Above Average Analyst Target. In recent trading shares of Regeneron Pharmaceuticals Inc. (Symbol: REGN) have crossed above the average analyst 12-month target price of $797.92 changing hands for $812.27/share. When a stock reaches the target an analyst has set the analyst logically has two ways to react:
Thu Jan 8, 2026
B of A Securities Upgrades Regeneron Pharmaceuticals (REGN). Fintel reports that on January 7 2026 B of A Securities upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Underperform to Buy. Analyst Price Forecast Suggests 4.08% Upside
Wed Jan 7, 2026
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?. Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Wed Jan 7, 2026
Regeneron Just Moved From Underperform To Buy - Heres Why. Could the tide be turning for ) after a surprising shift in analyst sentiment?As investors digest the latest upgrade what factors are driving this newfound optimism for the biotech giant?.Analyst Tazeen Ahmad upgraded Regeneron from Underperform to Buy and raised the price .BofA'.s prior Underperform thesis on Eylea SD has primarily played out with consensus estimates moving lower. Analyst Ahmad is increasingly constructive on Eylea
Wed Jan 7, 2026
Regeneron upgraded at BoA on Eylea HD Dupixent and pipeline.
Wed Jan 7, 2026
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?. Regeneron shares are up 41% in six months as FDA approvals strong Dupixent profits and oncology gains lift investor confidence.
Fri Jan 2, 2026
Benjamin Graham Detailed Fundamental Analysis - REGN. Below is Valideas guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav
Mon Dec 29, 2025
Benjamin Graham Detailed Fundamental Analysis - REGN. Below is Valideas guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow REGN rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav
Fri Dec 26, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
REGN Stock trends
REGN Stock performance
REGN Stock analysis
REGN investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.